Online citations, reference lists, and bibliographies.
← Back to Search

Revisions In The International System For Staging Lung Cancer.

C. Mountain
Published 1997 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Revisions in stage grouping of the TNM subsets (T=primary tumor, N=regional lymph nodes, M=distant metastasis) in the International System for Staging Lung Cancer have been adopted by the American Joint Committee on Cancer and the Union Internationale Contre le Cancer. These revisions were made to provide greater specificity for identifying patient groups with similar prognoses and treatment options with the least disruption of the present classification: T1N0M0, stage IA; T2N0M0, stage IB; T1N1M0, stage IIA; T2N1M0 and T3N0M0, stage IIB; and T3N1M0, T1N2M0, T2N2M0, T3N2M0, stage IIIA. The TNM subsets in stage IIIB-T4 any N M0, any T N3M0, and in stage IV-any T any N M1, remain the same. Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.
This paper references
Statistical methods for survival time studies
MJ Staquet (1975)
10.1093/JNCI/88.17.1210
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
R. Dillman (1996)
10.1016/S0954-6111(96)90128-6
Adenocarcinoma of the lung--clinical features and survival.
D. Dev (1996)
Enquete permanent dans les centres antercan - cereux
PF Denoix (1946)
10.1016/S0039-6109(16)44330-6
A new international staging system for lung cancer.
C. Mountain (1986)
10.1016/0895-4356(95)00518-8
Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
M. Brundage (1996)
Present views of the surgical treatment of non-small cell lung cancer.
L. Lacquet (1994)
Lung cancer staging classification.
C. Mountain (1993)
Present views of the surgical treatment of non-small cell lung cancer.
Lacquet Lk (1994)
10.1378/CHEST.101.4.1013
The effect of surgical treatment on survival from early lung cancer. Implications for screening.
B. Flehinger (1992)
10.1016/0169-5002(95)90214-7
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
D. Harpole (1995)
10.1093/milmed/156.9.479
Non-small cell lung cancer: treatment results at a USAF referral center.
B. Prestidge (1991)
The birth of TNM
DH Harpole (1988)
The effect of surgical treatment on sunival from early lung cancer : impli ¬ cations for screening
Brundage (1992)
10.1177/028418519503600440
Survival of Patients after Resection for Lung Cancer
S. Lähde (1995)
10.1378/CHEST.89.4_SUPPLEMENT.225S
The new International Staging System for Lung Cancer.
C. Mountain (1987)



This paper is referenced by
10.1158/1078-0432.CCR-04-2013
Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer
Z. Hu (2005)
10.1002/ijc.10795
Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer
H. Nakamura (2003)
10.1111/j.1349-7006.2011.02197.x
Overexpression of T‐LAK cell‐originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma
Di-Cing Wei (2012)
10.1111/j.1349-7006.2006.00160.x
Depression and survival in patients with non‐small cell lung cancer after curative resection: a preliminary study
N. Nakaya (2006)
10.1378/CHEST.113.6.1728
Reflections on the Revisions in the International System for Staging Lung Cancer
R. Rami-Porta (1998)
10.1016/S0169-5002(99)00036-7
Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer.
C. Dazzi (1999)
10.1016/S1010-7940(99)00082-2
Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy.
P. D. De Leyn (1999)
10.1002/cncr.21885
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer
R. Booton (2006)
10.1002/ijc.10347
Clinical significance of caspase‐3 expression in pathologic‐stage I, nonsmall‐cell lung cancer
T. Takata (2001)
10.1002/cncr.20156
Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma
H. Chang (2004)
10.1002/(SICI)1097-0142(19991001)86:7<1165::AID-CNCR10>3.0.CO;2-9
Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung
O. Breathnach (1999)
10.1002/cncr.21087
Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma
Kuan-Yu Chen (2005)
10.1002/cncr.20827
Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma
R. Tanaka (2005)
10.1136/thx.2008.098913
An integrated home oxygen service saves £130 000 per year on home oxygen tariffs
C. Deeming (2008)
Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
G. Cox (2000)
10.1007/S002680020015
Advances in the Staging of Intrathoracic Malignancies
M. Whyte (2001)
10.1136/thorax.56.7.561
A biological staging model for operable non-small cell lung cancer
G. Cox (2001)
10.1016/S1010-7940(01)00777-1
Improved pre-operative mediastinal staging in non-small-cell lung cancer by serial sectioning and immunohistochemical staining of lymph-node biopsies.
J. W. Oosterhuis (2001)
10.1016/S0169-5002(01)00312-9
Chemotherapy in stage IV lung cancer (take home messages).
W. Eberhardt (2001)
10.1016/S0169-5002(01)00296-3
Principles of surgical treatment in localized non-small cell lung cancer.
H. Dienemann (2001)
10.1097/00129039-200206000-00002
Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
A. Haque (2002)
10.1016/S0169-5002(01)00426-3
Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes.
P. Yang (2002)
10.1016/S0002-9440(10)64921-8
Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor.
E. Laack (2002)
10.1016/S0169-5002(02)00009-0
Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
N. Reinmuth (2002)
10.1148/RADIOL.2241011189
Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings.
J. Collins (2002)
10.1016/S0039-6109(02)00019-1
Multi-modality treatment of non-small cell lung cancer.
R. Feins (2002)
10.1586/14737140.2.4.385
Radiologic screening for lung cancer
G. Bastarrika (2002)
10.1016/S1134-2072(02)75620-X
Estado actual en el tratamiento del cáncer
A. M. Borinaga (2002)
10.1097/00042423-200211000-00002
Use of Magnetic Resonance Imaging in the Staging of Lung Cancer
A. Rajesh (2002)
10.1007/978-0-387-68113-9_75
Pleura: Anatomy, Physiology, and Disorders
J. Friedberg (2008)
10.1378/CHEST.123.1_SUPPL.137S
Noninvasive staging of non-small cell lung cancer: a review of the current evidence.
E. Toloza (2003)
10.1016/S0169-5002(03)91955-6
Quantification of free circulating DNA as a diagnostic marker in lung cancer.
G. Sozzi (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar